← Drug database

Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine;tenofovir disoproxil)

Generic
Region
🇪🇺 EU
Active substance
emtricitabine;tenofovir disoproxil
Company
Zentiva k.s.
Status
Authorised
Therapeutic area
HIV Infections
CHMP opinion
Thu 15 Sep 2016
EU approval
Wed 09 Nov 2016
Designations
Generic
Application
EMEA/H/C/004137
ATC
J05AR03
Official record
www.ema.europa.eu

Indication

Treatment of HIV-1 infection Emtricitabine/Tenofovir disoproxil Zentiva is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents. Pre-exposure prophylaxis (PrEP) Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Emtricitabine/Tenofovir disoproxil Zentiva

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.